Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.

doi:10.1182/blood.2020010572

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.

Blood - 4 Nov 2021

Sacco Antonio, Federico Cinzia, Todoerti Katia, Ziccheddu Bachisio, Palermo Valentina, Giacomini Arianna, Ravelli Cosetta, Maccarinelli Federica, Bianchi Giada, Belotti Angelo, Ribolla Rossella, Favasuli Vanessa, Revenko Alexey S, Macleod A Robert, Willis Brandon, Cai Hongbo, Hauser Joana, Rooney Claire, Willis Sophie E, Martin Philip Lloyd, Staniszewska Anna, Ambrose Helen, Hanson Lyndsey, Cattaneo Chiara, Tucci Alessandra, Rossi Giuseppe, Ronca Roberto, Neri Antonino, Mitola Stefania, Bolli Niccolò, Presta Marco, Moschetta Michele, Ross Sarah, Roccaro Aldo M

Abstract excerpt

Alterations in KRAS have been identified as the most recurring somatic variants in the multiple myeloma (MM) mutational landscape. Combining DNA and RNA sequencing, we studied 756 patients and observed KRAS as the most frequently mutated gene in patients at diagnosis; in addition, we demonstrated the persistence or de novo occurrence of the KRAS aberration at disease relapse. Small-molecule inhibitors targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, SCID

Share to Molecular Targeted Therapy

Share to Multiple Myeloma

Share to Neoplasm Recurrence, Local

Share to Oligonucleotides, Antisense

Share to Proto-Oncogene Proteins p21(ras)

Share to Small Molecule Libraries

Source

Open in PubMed Open full text

Identifiers

PMID: 34077955
DOI: 10.1182/blood.2020010572
PMCID: PMC9710471

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.PMID 34077955Read ↗

Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell LinesSemantic proximity Read ↗

Targeting the BRAF V600E mutation in multiple myeloma.Semantic proximity Read ↗

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.Semantic proximity Read ↗

ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m6A-demethylation of SAV1 mRNA and Myeloma Stem Cell Phenotype.Semantic proximity Read ↗

The mutagenic impact of melphalan in multiple myeloma.Semantic proximity Read ↗

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.Semantic proximity Read ↗

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.Semantic proximity Read ↗

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myelomaSemantic proximity Read ↗

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.Semantic proximity Read ↗

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma.Semantic proximity Read ↗

Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity.Semantic proximity Read ↗

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.